PURPOSE: While studies have found that adjuvant hormonal therapy for hormone-sensitive breast cancer (BC) dramatically reduces recurrence and mortality, adherence to medications is suboptimal. We investigated the rates and predictors of early discontinuation and nonadherence to hormonal therapy in patients enrolled in Kaiser Permanente of Northern California health system. PATIENTS AND METHODS: We identified women diagnosed with hormone-sensitive stage I-III BC from 1996 to 2007 and used automated pharmacy records to identify hormonal therapy prescriptions and dates of refill. We used Cox proportional hazards regression models to analyze factors associated with early discontinuation and nonadherence (medication possession ratio < 80%) of hormonal therapy. RESULTS: We identified 8,769 patients with BC who met our eligibility criteria and who filled at least one prescription for tamoxifen (43%), aromatase inhibitors (26%), or both (30%) within 1 year of diagnosis. Younger or older age, lumpectomy (v mastectomy), and comorbidities were associated with earlier discontinuation, while Asian race, being married, earlier year at diagnosis, receipt of chemotherapy or radiotherapy, and longer prescription refill interval were associated with completion of 4.5 years of therapy. Of those who continued therapy, similar factors were associated with full adherence. Women age younger than 40 years had the highest risk of discontinuation (hazard ratio, 1.51; 95% CI, 1.23 to 1.85). By 4.5 years, 32% discontinued therapy, and of those who continued, 72% were fully adherent. CONCLUSION: Only 49% of patients with BC took adjuvant hormonal therapy for the full duration at the optimal schedule. Younger women are at high risk of nonadherence. Interventions to improve adherence and continuation of hormonal therapy are needed, especially for younger women.
PURPOSE: While studies have found that adjuvant hormonal therapy for hormone-sensitive breast cancer (BC) dramatically reduces recurrence and mortality, adherence to medications is suboptimal. We investigated the rates and predictors of early discontinuation and nonadherence to hormonal therapy in patients enrolled in Kaiser Permanente of Northern California health system. PATIENTS AND METHODS: We identified women diagnosed with hormone-sensitive stage I-III BC from 1996 to 2007 and used automated pharmacy records to identify hormonal therapy prescriptions and dates of refill. We used Cox proportional hazards regression models to analyze factors associated with early discontinuation and nonadherence (medication possession ratio < 80%) of hormonal therapy. RESULTS: We identified 8,769 patients with BC who met our eligibility criteria and who filled at least one prescription for tamoxifen (43%), aromatase inhibitors (26%), or both (30%) within 1 year of diagnosis. Younger or older age, lumpectomy (v mastectomy), and comorbidities were associated with earlier discontinuation, while Asian race, being married, earlier year at diagnosis, receipt of chemotherapy or radiotherapy, and longer prescription refill interval were associated with completion of 4.5 years of therapy. Of those who continued therapy, similar factors were associated with full adherence. Women age younger than 40 years had the highest risk of discontinuation (hazard ratio, 1.51; 95% CI, 1.23 to 1.85). By 4.5 years, 32% discontinued therapy, and of those who continued, 72% were fully adherent. CONCLUSION: Only 49% of patients with BC took adjuvant hormonal therapy for the full duration at the optimal schedule. Younger women are at high risk of nonadherence. Interventions to improve adherence and continuation of hormonal therapy are needed, especially for younger women.
Authors: Linda C Harlan; Jeffrey Abrams; Joan L Warren; Lin Clegg; Jennifer Stevens; Rachel Ballard-Barbash Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: Rebecca A Silliman; Edward Guadagnoli; William Rakowski; Mary Beth Landrum; Timothy L Lash; Robert Wolf; Aliza Fink; Patricia A Ganz; Jerry Gurwitz; Catherine Borbas; Vincent Mor Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: Ann M Geiger; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Marianne N Prout; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Shelley M Enger; Rebecca A Silliman Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Dawn L Hershman; Xiaoyan Wang; Russell McBride; Judith S Jacobson; Victor R Grann; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2006-04-01 Impact factor: 4.872
Authors: Rachel L Yung; Michael J Hassett; Kun Chen; Foster C Gesten; Patrick J Roohan; Francis P Boscoe; Amber H Sinclair; Maria J Schymura; Deborah Schrag Journal: J Natl Cancer Inst Date: 2012-07-06 Impact factor: 13.506
Authors: Ekim Ekinci; Salima Nathoo; Thushara Korattyil; Aisha Vadhariya; Hanna A Zaghloul; Polly A Niravath; Susan M Abughosh; Meghana V Trivedi Journal: J Cancer Surviv Date: 2018-02-02 Impact factor: 4.442
Authors: Jun J Mao; Annie Chung; Adrian Benton; Shawndra Hill; Lyle Ungar; Charles E Leonard; Sean Hennessy; John H Holmes Journal: Pharmacoepidemiol Drug Saf Date: 2013-01-16 Impact factor: 2.890
Authors: S P Krotneva; A Ramjaun; K E Reidel; T Eguale; N Trabulsi; N Mayo; R Tamblyn; A N Meguerditchian Journal: Curr Oncol Date: 2014-02 Impact factor: 3.677
Authors: Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby Journal: Cancer Prev Res (Phila) Date: 2014-05-09